Addex Therapeutics Ltd (ADXN) FinancialsADXNAddex Therapeutics Ltd

Evaluating the bottom line, Addex Therapeutics Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -150.99%, provide a clear picture of how effectively ADXN converts its operational activities into shareholder value.

In the context of the broader market, ADXN competes directly with industry leaders such as MBIO and JUNS. With a market capitalization of $5.06M, it holds a leading position in the sector. When comparing efficiency, ADXN's gross margin of N/A stands against MBIO's N/A and JUNS's 86.88%. Such benchmarking helps identify whether Addex Therapeutics Ltd is trading at a premium or discount relative to its financial performance.

Addex has reported a net loss of CHF 3.46 million for H1 2026, with a gross margin fluctuating around 100% in previous quarters but showing losses in recent quarters. The current ratio has dropped to 0.76, indicating potential liquidity issues.